Intriguingly, for five out of the six CML patients examined, GDPD3 mRNA levels were indeed higher in CD34+ cells isolated after imatinib therapy than in CD34+ cells isolated before treatment (Fig. 6d). This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.